Summary
This 8-K filing from Johnson & Johnson, dated May 14, 2018, primarily provides updated sales information for its Medical Devices segment, specifically concerning the Cerenovus business. The key disclosure is the reclassification of $156 million in 2016 sales data, moving it from the Orthopaedics category to Interventional Solutions. This adjustment is to align with current product disclosure practices and accurately reflect the scope of the Cerenovus business, which now encompasses the Codman Neurovascular business and recent acquisitions like Neuravi and Pulsar. Investors should note that this filing is for informational purposes related to financial reporting adjustments. It does not announce any new strategic initiatives, major financial results, or significant operational changes. The reclassification primarily impacts historical segment reporting within Medical Devices and aims to provide a clearer picture of the Interventional Solutions and Orthopaedics product lines going forward. The company also notes that prior quarter amounts have been reclassified to conform to current quarter product disclosures, indicating a commitment to consistent reporting.
Key Highlights
- 1Johnson & Johnson is reclassifying $156 million in 2016 sales from Orthopaedics to Interventional Solutions.
- 2This reclassification is related to the Cerenovus business, which has been expanded through acquisitions and now includes Codman Neurovascular.
- 3The filing clarifies that Cerenovus was previously part of Spine & Other within Orthopaedics.
- 4The company is aligning historical sales data to reflect current product disclosure practices.
- 5Prior quarter amounts have also been reclassified for consistency in reporting.
- 6This filing is a Regulation FD Disclosure, providing supplemental sales information.